Cleanroom + Data Centre Commissioning + Qualification — ASHRAE Guideline 0 + ISPE C+Q + ISO 14644-3

Cleanroom + Tier-IV Data Centre Commissioning + Qualification per ASHRAE Guideline 0 + ISPE Baseline + ISO 14644-3 + USFDA cGMP costs 5 % of project capex but returns ₹128 Cr saving over 3 years (energy + avoided rework + faster regulatory + reduced insurance + warranty). Indian projects skip OQ + PQ to save 3-4 % capex + fail USFDA inspection or Uptime Tier IV cert on day 90 + lose ₹500-1500 Cr revenue. Three failures: OQ skipped going straight to occupancy missing system-under-load verification, Cx agent is the EPC contractor violating ASHRAE Guideline 0 independence, no URS-to-PQ traceability matrix blocking regulator audit.

Cleanroom + IDC commissioning — the discipline that saves the project

Pharma cleanroom + Data Centre (IDC) commissioning is where ₹50-500 Cr projects either succeed or fail. ISPE Baseline Guide Commissioning + Qualification + ASHRAE Guideline 0 + ASHRAE Guideline 1.4 + ISO 14644-3 (Cleanroom Test Methods) + IECC Cooperation on Computer Room Cooling + Uptime Tier Certification + USFDA cGMP Validation + WHO TRS 1019 all describe a 4-phase Commissioning + Qualification (C&Q) pathway — Design Qualification + Installation Qualification + Operational Qualification + Performance Qualification (DQ + IQ + OQ + PQ). Indian projects skip OQ + PQ for cost — fail USFDA inspection or Uptime cert.

Commissioning + Qualification scope — 28-nm fab + 6 MW Tier-IV IDC

Three Indian C&Q failures that kill compliance + revenue

1. OQ skipped — straight to occupancy — most Indian pharma + IDC projects do IQ then declare project complete. OQ (system-under-load verification) catches AHU sequence faults + chiller hunting that destroy first 6 months of operation. USFDA inspection fails on day 90.
2. Cx agent is the EPC contractor — independence requirement under ASHRAE Guideline 0 + ISPE — Cx agent must be third-party, not the contractor verifying their own work. Indian projects use EPC = conflict of interest = missed defects.
3. No URS-to-PQ traceability matrix — User Requirements Specification must trace to PQ acceptance criteria. Without traceability matrix the regulator cannot audit. USFDA + WHO + Uptime all demand evidence + most Indian projects produce only summary reports.